AAGP comments to FDA
As a member of the LEAD coalition, AAGP submitted formal comments to the U.S. Food and Drug Administration in support of the adoption of its draft guidance on drug efficacy. The draft guidance outlines the FDA's current thinking on how a drug developer may demonstrate efficacy in clinical trials in individuals in the early stages of Alzheimer's disease before the onset of overt dementia.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063